107 related articles for article (PubMed ID: 30267450)
1. In vitro effects of the chemotherapy agent water-soluble micellar paclitaxel (Paccal Vet) on canine hemangiosarcoma cell lines.
Reckelhoff CR; Lejeune A; Thompson PM; Shiomitsu K
Vet Comp Oncol; 2019 Mar; 17(1):32-41. PubMed ID: 30267450
[TBL] [Abstract][Full Text] [Related]
2. In vitro effects of Yunnan Baiyao on canine hemangiosarcoma cell lines.
Wirth KA; Kow K; Salute ME; Bacon NJ; Milner RJ
Vet Comp Oncol; 2016 Sep; 14(3):281-94. PubMed ID: 24976212
[TBL] [Abstract][Full Text] [Related]
3. A dose-finding study with a novel water-soluble formulation of paclitaxel for the treatment of malignant high-grade solid tumours in dogs.
von Euler H; Rivera P; Nyman H; Häggström J; Borgå O
Vet Comp Oncol; 2013 Dec; 11(4):243-55. PubMed ID: 22404965
[TBL] [Abstract][Full Text] [Related]
4. Clinical efficacy and safety of a water-soluble micellar paclitaxel (Paccal Vet) in canine mastocytomas.
Rivera P; Akerlund-Denneberg N; Bergvall K; Kessler M; Rowe A; Willmann M; Persson G; Kastengren Fröberg G; Westberg S; von Euler H
J Small Anim Pract; 2013 Jan; 54(1):20-7. PubMed ID: 23190121
[TBL] [Abstract][Full Text] [Related]
5. In vitro effects of the tyrosine kinase inhibitor, masitinib mesylate, on canine hemangiosarcoma cell lines.
Lyles SE; Milner RJ; Kow K; Salute ME
Vet Comp Oncol; 2012 Sep; 10(3):223-35. PubMed ID: 22594682
[TBL] [Abstract][Full Text] [Related]
6. A randomized trial investigating the efficacy and safety of water soluble micellar paclitaxel (Paccal Vet) for treatment of nonresectable grade 2 or 3 mast cell tumors in dogs.
Vail DM; von Euler H; Rusk AW; Barber L; Clifford C; Elmslie R; Fulton L; Hirschberger J; Klein M; London C; Martano M; McNiel EA; Morris JS; Northrup N; Phillips B; Polton G; Post G; Rosenberg M; Ruslander D; Sahora A; Siegel S; Thamm D; Westberg S; Winter J; Khanna C
J Vet Intern Med; 2012; 26(3):598-607. PubMed ID: 22390318
[TBL] [Abstract][Full Text] [Related]
7. In vitro effects of the activity of novel platinum (II) complex in canine and human cell lines.
Henklewska M; Pawlak A; Kutkowska J; Pruchnik H; Rapak A; Obminska-Mrukowicz B
Vet Comp Oncol; 2019 Dec; 17(4):497-506. PubMed ID: 31111625
[TBL] [Abstract][Full Text] [Related]
8. Anticancer effects of resveratrol in canine hemangiosarcoma cell lines.
Carlson A; Alderete KS; Grant MKO; Seelig DM; Sharkey LC; Zordoky BNM
Vet Comp Oncol; 2018 Jun; 16(2):253-261. PubMed ID: 29235249
[TBL] [Abstract][Full Text] [Related]
9. In vitro effects of PI3K/mTOR inhibition in canine hemangiosarcoma.
Pyuen AA; Meuten T; Rose BJ; Thamm DH
PLoS One; 2018; 13(7):e0200634. PubMed ID: 30011343
[TBL] [Abstract][Full Text] [Related]
10. Apoptotic mechanism of paclitaxel-induced cell death in human head and neck tumor cell lines.
Hsiao JR; Leu SF; Huang BM
J Oral Pathol Med; 2009 Feb; 38(2):188-97. PubMed ID: 19200178
[TBL] [Abstract][Full Text] [Related]
11. Addition of 5-fluorouracil to doxorubicin-paclitaxel sequence increases caspase-dependent apoptosis in breast cancer cell lines.
Zoli W; Ulivi P; Tesei A; Fabbri F; Rosetti M; Maltoni R; Giunchi DC; Ricotti L; Brigliadori G; Vannini I; Amadori D
Breast Cancer Res; 2005; 7(5):R681-9. PubMed ID: 16168113
[TBL] [Abstract][Full Text] [Related]
12. Synergistic anticancer effects achieved by co-delivery of TRAIL and paclitaxel using cationic polymeric micelles.
Lee AL; Wang Y; Pervaiz S; Fan W; Yang YY
Macromol Biosci; 2011 Feb; 11(2):296-307. PubMed ID: 21154473
[TBL] [Abstract][Full Text] [Related]
13. A novel combined micellar system of lapatinib and Paclitaxel with enhanced antineoplastic effect against human epidermal growth factor receptor-2 positive breast tumor in vitro.
Wei Y; Xu S; Wang F; Zou A; Zhang S; Xiong Y; Cao S; Zhang Q; Wang Y; Jiang X
J Pharm Sci; 2015 Jan; 104(1):165-77. PubMed ID: 25421492
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic potential of endothelin inhibitors in canine hemangiosarcoma.
Fukumoto S; Saida K; Sakai H; Ueno H; Iwano H; Uchide T
Life Sci; 2016 Aug; 159():55-60. PubMed ID: 26835989
[TBL] [Abstract][Full Text] [Related]
15. High drug efflux pump capacity and low DNA damage response induce doxorubicin resistance in canine hemangiosarcoma cell lines.
Morita A; Aoshima K; Gulay KCM; Onishi S; Shibata Y; Yasui H; Kobayashi A; Kimura T
Res Vet Sci; 2019 Dec; 127():1-10. PubMed ID: 31648115
[TBL] [Abstract][Full Text] [Related]
16. Association of Sphingosine-1-phosphate (S1P)/S1P Receptor-1 Pathway with Cell Proliferation and Survival in Canine Hemangiosarcoma.
Rodriguez AM; Graef AJ; LeVine DN; Cohen IR; Modiano JF; Kim JH
J Vet Intern Med; 2015; 29(4):1088-97. PubMed ID: 26118793
[TBL] [Abstract][Full Text] [Related]
17. Preclinical pharmacologic evaluation of MST-997, an orally active taxane with superior in vitro and in vivo efficacy in paclitaxel- and docetaxel-resistant tumor models.
Sampath D; Greenberger LM; Beyer C; Hari M; Liu H; Baxter M; Yang S; Rios C; Discafani C
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3459-69. PubMed ID: 16740771
[TBL] [Abstract][Full Text] [Related]
18. Effects of inhibitors of vascular endothelial growth factor receptor 2 and downstream pathways of receptor tyrosine kinases involving phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin or mitogen-activated protein kinase in canine hemangiosarcoma cell lines.
Adachi M; Hoshino Y; Izumi Y; Sakai H; Takagi S
Can J Vet Res; 2016 Jul; 80(3):209-16. PubMed ID: 27408334
[TBL] [Abstract][Full Text] [Related]
19. Sunitinib can enhance BCG mediated cytotoxicity to transitional cell carcinoma through apoptosis pathway.
Ping SY; Wu CL; Yu DS
Urol Oncol; 2012 Sep; 30(5):652-9. PubMed ID: 20884251
[TBL] [Abstract][Full Text] [Related]
20. Antitumor effects of SB injection in canine osteosarcoma and melanoma cell lines.
Kweon K; Ahn JO; Song WJ; Li Q; Lee BY; Chae HK; Youn HY
In Vitro Cell Dev Biol Anim; 2019 Jan; 55(1):7-16. PubMed ID: 30382494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
